Intas Pharmaceuticals Limited, one of the leading pharmaceutical organisations in India,
has reinforced its oncology product range by successfully introducing
the Azacitidine molecule in Azadine for the first time in India.
Azacitidine induces antineoplastic activity via two mechanisms;
inhibition of DNA methyltransferase at low doses, causing
hypomethylation of DNA, and direct cytotoxicity in abnormal
hematopoietic cells in the bone marrow through its incorporation into
DNA and RNA at high doses, resulting into tumourous cell death.
Azacitidine has been approved by the U.S. FDA since May, 2004.
Myelodysplastic Syndrome (MDS) is a type of cancer in which the bone marrow does not make enough healthy blood cells and there are abnormal (blast) cells in the blood and/or in the bone marrow. Advanced stages of MDS may lead to Acute Myelogenous Leukemia (AML). It is estimated that 4-5 people per 1,00,000 suffer from MDS/AML. Data extrapolated to Indian population from global epidemiologic studies suggest that the disease burden of MDS in India is likely to be sizeable. Also, cytogenetic studies suggest that MDS patients in India get affected by the disease at a younger age and also tend to have a 'higher risk'.
Currently, for combating this type of cancer in the country, oncologists have to rely on an imported version of Azacitidine. The treatment cost of imported Azacitidine can range anywhere between Rs 15 to 18 lakh. The cost of treatment with other options, ranging from conventional agents to transplants, is estimated to cost between Rs 2 to 15 lakh. Azadine has been priced with an objective to make it accessible to a majority of the needy patients. It is priced at 1/5th of the innovator brand. Azacitidine is the only drug, which has been shown to prolong overall survival duration, prolong time to transformation into AML, increase response rate, reduce transfusion burden and improve quality of life. Azacitidine will also offer better convenience and compliance and reduce hospital visits due to subcutaneous administration.
Azadine is manufactured at the state-of-the-art Intas SEZ facility in Ahmedabad, Gujarat, which is spread over 35,565 sq. mts. The plant has dedicated manufacturing facilities for cytotoxic formulations (tablet, capsule, liquid injection, lyophilized injection, ointment) and other oral solids (tablets, capsules). This plant operates in compliance with global regulatory standards like USFDA, MHRA and ANVISA.
For more information, visit www.intaspharma.com
SOURCE Intas Pharmaceuticals Ltd
Myelodysplastic Syndrome (MDS) is a type of cancer in which the bone marrow does not make enough healthy blood cells and there are abnormal (blast) cells in the blood and/or in the bone marrow. Advanced stages of MDS may lead to Acute Myelogenous Leukemia (AML). It is estimated that 4-5 people per 1,00,000 suffer from MDS/AML. Data extrapolated to Indian population from global epidemiologic studies suggest that the disease burden of MDS in India is likely to be sizeable. Also, cytogenetic studies suggest that MDS patients in India get affected by the disease at a younger age and also tend to have a 'higher risk'.
Currently, for combating this type of cancer in the country, oncologists have to rely on an imported version of Azacitidine. The treatment cost of imported Azacitidine can range anywhere between Rs 15 to 18 lakh. The cost of treatment with other options, ranging from conventional agents to transplants, is estimated to cost between Rs 2 to 15 lakh. Azadine has been priced with an objective to make it accessible to a majority of the needy patients. It is priced at 1/5th of the innovator brand. Azacitidine is the only drug, which has been shown to prolong overall survival duration, prolong time to transformation into AML, increase response rate, reduce transfusion burden and improve quality of life. Azacitidine will also offer better convenience and compliance and reduce hospital visits due to subcutaneous administration.
Azadine is manufactured at the state-of-the-art Intas SEZ facility in Ahmedabad, Gujarat, which is spread over 35,565 sq. mts. The plant has dedicated manufacturing facilities for cytotoxic formulations (tablet, capsule, liquid injection, lyophilized injection, ointment) and other oral solids (tablets, capsules). This plant operates in compliance with global regulatory standards like USFDA, MHRA and ANVISA.
About Intas
Intas
is a leading multi-specialty pharmaceutical organisation committed to
deliver affordable and innovative pharmaceutical solutions. The company
is now the 12th largest pharmaceutical company in the domestic market (as per IMS Health India, Secondary Stockist Audit (SSA), April 2014
MAT). Intas is one of the leading players in chronic therapy in the
domestic market. Its portfolio extends to central nervous system (CNS,
cardiovascular system (CVS), oncology, diabetes, gastroenterology, pain
management, urology, nephrology, gynecology, infertility and respiratory
care. Intas has a presence in more than 70 countries worldwide with a
robust sales, marketing and distribution infrastructure in highly
regulated markets like North America, Europe, South Africa, Australia and New Zealand among others.For more information, visit www.intaspharma.com
Media Contact: Pritesh Trivedi, priteshtrivedi@oneadvt.com, +91-9727260309, Manager - PR, One Advertising & Communication Services Ltd.
SOURCE Intas Pharmaceuticals Ltd
No comments:
Post a Comment